Evidence map›Paper›PMID 29584756›Full record

Trial reportPloS one2018

Transcriptional signature associated with early rheumatoid arthritis and healthy individuals at high risk to develop the disease.

N Macías-Segura, J E Castañeda-Delgado, Y Bastian, D Santiago-Algarra, J D Castillo-Ortiz, A L Alemán-Navarro, E Jaime-Sánchez, M Gomez-Moreno, C A Saucedo-Toral, Edgar E Lara-Ramírez and 5 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Role of HDAC5 Epigenetics in Chronic Craniofacial Neuropathic Pain.International journal of molecular sciences · 2024
    Review
  5. Role of IFN-α in Rheumatoid Arthritis.Current rheumatology reports · 2024
    Review
  6. The Role of the Transcriptional Coactivator BOB.1/OBF.1 in Adaptive Immunity.Advances in experimental medicine and biology · 2024
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

N Macías-SeguraUnidad de Investigación Biomédica de Zacatecas, IMSS, Zacatecas, México.
J E Castañeda-DelgadoCatedras-CONACyT, Unidad de Investigación Biomédica de Zacatecas-IMSS, Zacatecas, México.ORCID 0000-0003-2124-2036
Y BastianCatedras-CONACyT, Unidad de Investigación Biomédica de Zacatecas-IMSS, Zacatecas, México.
D Santiago-AlgarraUnidad de Investigación Biomédica de Zacatecas, IMSS, Zacatecas, México.
J D Castillo-OrtizUnidad de Investigación en Enfermedades Crónico-Degenerativas, Guadalajara, México.
A L Alemán-NavarroUnidad de Investigación Biomédica de Zacatecas, IMSS, Zacatecas, México.
E Jaime-SánchezUnidad de Investigación Biomédica de Zacatecas, IMSS, Zacatecas, México.
M Gomez-MorenoUnidad de Investigación Biomédica de Zacatecas, IMSS, Zacatecas, México.
C A Saucedo-ToralUnidad de Investigación Biomédica de Zacatecas, IMSS, Zacatecas, México.
Edgar E Lara-RamírezUnidad de Investigación Biomédica de Zacatecas, IMSS, Zacatecas, México.
M Zapata-ZuñigaFacultad de Medicina Humana y Ciencias de la Salud, Universidad Autonoma de Zacatecas, Hospital Rural #51, IMSS, Villanueva, Zacatecas, México.
L Enciso-MorenoUnidad de Investigación Biomédica de Zacatecas, IMSS, Zacatecas, México.
R González-AmaroDepartamento de Inmunología, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, México.
C Ramos-RemusUnidad de Investigación en Enfermedades Crónico-Degenerativas, Guadalajara, México.
J A Enciso-MorenoUnidad de Investigación Biomédica de Zacatecas, IMSS, Zacatecas, México.
Universidad Autónoma de Zacatecas "Francisco García Salinas" · MXAutonomous University of San Luis Potosí · MXInstitute for Scientific and Technological Research · MXUniversidad Autónoma de Guadalajara · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLittle is known regarding the mechanisms underlying the loss of tolerance in the early and preclinical stages of autoimmune diseases. The aim of this work was to identify the transcriptional profile and signaling pathways associated to non-treated early rheumatoid arthritis (RA) and subjects at high risk. Several biomarker candidates for early RA are proposed.

methodsWhole blood total RNA was obtained from non-treated early RA patients with <1 year of evolution as well as from healthy first-degree relatives of patients with RA (FDR) classified as ACCP+ and ACCP- according to their antibodies serum levels against cyclic citrullinated peptides. Complementary RNA (cRNA) was synthetized and hybridized to high-density microarrays. Data was analyzed in Genespring Software and functional categories were assigned to a specific transcriptome identified in subjects with RA and FDR ACCP positive. Specific signaling pathways for genes associated to RA were identified. Gene expression was evaluated by qPCR. Receiver operating characteristic (ROC) analysis was used to evaluate these genes as biomarkers.

resultsA characteristic transcriptome of 551 induced genes and 4,402 repressed genes were identified in early RA patients. Bioinformatics analysis of the data identified a specific transcriptome in RA patients. Moreover, some overlapped transcriptional profiles between patients with RA and ACCP+ were identified, suggesting an up-regulated distinctive transcriptome from the preclinical stages up to progression to an early RA state. A total of 203 pathways have up-regulated genes that are shared between RA and ACCP+. Some of these genes show potential to be used as progression biomarkers for early RA with area under the curve of ROC > 0.92. These genes come from several functional categories associated to inflammation, Wnt signaling and type I interferon pathways.

conclusionThe presence of a specific transcriptome in whole blood of RA patients suggests the activation of a specific inflammatory transcriptional signature in early RA development. The set of overexpressed genes in early RA patients that are shared with ACCP+ subjects but not with ACCP- subjects, can represent a transcriptional signature involved with the transition of a preclinical to a clinical RA stage. Some of these particular up-regulated and down-regulated genes are related to inflammatory processes and could be considered as biomarker candidates for disease progression in subjects at risk to develop RA.

Indexed as

Arthritis, RheumatoidGene Expression ProfilingGene Expression RegulationSignal TransductionAdultBiomarkersCross-Sectional StudiesFemaleHumansMaleMiddle AgedRisk FactorsBiomarkers

Identifiers

PMID29584756
PMCPMC5870959
OpenAlexW2795144265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.